---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-003413"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2024-01-12T23:59:59+00:00"
generated_at: "2026-06-06T23:59:48.409194+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Onconetix CEO Neil Campbell resigns; interim CEO and Lead Independent Director appointed

## Summary
- Dr. Neil Campbell resigned as President, CEO, and board member effective Jan 10, 2024; no disagreement cited.
- Campbell receives $158,333 severance payment under a release of claims filed as Exhibit 99.1.
- Dr. Ralph Schiess, Chief Science Officer, appointed Interim CEO effective Jan 12, 2024.
- James Sapirstein named Lead Independent Director; will receive $40,000 per month for that role.

## SEC filing metadata
- accession: 0001213900-24-003413
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2024-01-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/ea191591-8k_onconetix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-003413
- JSON: https://secwatch.observer/filing/0001213900-24-003413.json
- Plain text: https://secwatch.observer/filing/0001213900-24-003413.txt

## Key facts
- Executive change
  Dr. Neil Campbell resigned as President and Chief Executive Officer at Onconetix, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: Effective as of January 10, 2024, Dr. Neil Campbell resigned as President and Chief Executive Officer and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm
- Executive change
  James Sapirstein was appointed as Lead Independent Director at Onconetix, Inc..
  - Action: appointed
  - Role: Lead Independent Director
  source text: Also on January 12, 2024, the Board appointed James Sapirstein, the current Non-Executive Chairman of the Board, to serve as Lead Independent Director pending the Board’s appointment of a permanent chief executive officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm
- Executive change
  Dr. Ralph Schiess was appointed as Interim Chief Executive Officer at Onconetix, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: On January 12, 2024, the Board appointed Dr. Ralph Schiess, the Company’s Chief Science Officer, to serve as the Company’s Interim Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/0001213900-24-003413-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.